GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets close in 6 hrs 22 mins

Gilead Sciences Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
69.36+0.07 (+0.10%)
As of 9:38AM EST. Market open.
People also watch
CELGBIIBAMGNREGNBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close69.29
Open69.11
Bid69.01 x 700
Ask69.24 x 100
Day's Range69.02 - 69.38
52 Week Range65.38 - 103.10
Volume383,111
Avg. Volume10,798,027
Market Cap90.86B
Beta1.03
PE Ratio (TTM)6.98
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (2.98%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal9 hours ago

    [$$] Gilead Goes to the Head of the Line

    Gilead Sciences’s approach to the biotech deals market involves more than just waiting.

  • American City Business Journals20 hours ago

    Did Gilead's new tool for speeding drug approval come at bargain-basement price?

    Gilead Sciences Inc. spent $125 million for a voucher that could speed FDA review of a drug, but one analyst said the seller may have undervalued the asset. Sarepta Therapeutics of Cambridge, Mass., on Tuesday said it sold the so-called priority review voucher to Foster City-based Gilead Sciences Inc. (GILD). Sarepta (SRPT) had received the rare pediatric disease voucher when the Food and Drug Administration approved its Duchenne muscular dystrophy drug, Exondys51, in September.

  • Investopedia23 hours ago

    Sarepta Sells Priority Review Voucher for $125M

    Sarepta sold its Priority Review Voucher for $125 million to Gilead.